idarubicin has been researched along with Blast Crisis in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.67) | 18.7374 |
| 1990's | 10 (33.33) | 18.2507 |
| 2000's | 11 (36.67) | 29.6817 |
| 2010's | 6 (20.00) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, J; Chen, Y; Dong, QF; Hu, JD; Li, F; Luo, LT; Sang, YQ; Wang, J; Wang, SL; Yang, T; Ye, YZ; Zhang, L; Zheng, J; Zheng, XY | 1 |
| Billingham, L; Brock, K; Copland, M; Siddique, S; Sirovica, M; Yap, C | 1 |
| Borrego-Hinojosa, J; Carrillo-Colmenero, AM; Liébana-Cañada, A; Pérez-del Barrio, Mdel P; Polaina-Rusillo, M; Ramírez-Tortosa, C | 1 |
| Cui, J; Gao, S; Han, W; Li, W; Liu, X; Su, L; Tan, Y; Yu, P | 1 |
| Cho, D; Kim, HJ; Kim, SH; Kim, TS; Lee, IK; Song, JH | 1 |
| Borthakur, G; Cortes, J; Jones, D; Kantarjian, HM; Luthra, R; Rios, MB; Verma, D; Verstovsek, S | 1 |
| Bencini, S; Bosi, A; Gianfaldoni, G; Longo, G; Mannelli, F; Ponziani, V; Vannucchi, AM | 1 |
| Celentano, M; Criscuolo, C; Ferrara, F; Izzo, T; Mele, G; Riccardi, C | 1 |
| Brizard, F; Canioni, D; Chomel, JC; Mayeur-Rousse, C; Randriamalala, E; Sorel, N; Turhan, AG; Voldoire, M | 1 |
| Antonioli, E; Baccini, M; Bosi, A; Gianfaldoni, G; Leoni, F; Mannelli, F | 1 |
| Du, X; Ke, XY; Liu, Y; Lu, ZS; Lv, JQ; Ma, J; Shen, ZX; Xu, XH; Zeng, XY; Zhan, ZM; Zhang, XH; Zhao, YM | 1 |
| Cortes, J; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; O'Brien, S; Quintás-Cardama, A; Ravandi, F; Thomas, D; Wierda, W | 1 |
| Chang, HJ; Cho, MS; Choi, MY; Kong, JH; Kwon, JM; Lee, KE; Lee, SM; Lee, SN; Mun, YC; Nam, E; Nam, SH; Seong, CM; Yoo, SH | 1 |
| Büchner, T; Creutzig, U; Döhner, H; Reinhardt, D; Sauerland, MC; Schlenk, RF; Zimmermann, M | 1 |
| Amutio, E; Bergua, JM; Brunet, S; de la Serna, J; Debén, G; Díaz-Mediavilla, J; Esteve, J; González, JD; González, M; León, A; Lowenberg, B; Milone, G; Montesinos, P; Negri, S; Parody, R; Rayón, C; Rivas, C; Sanz, MA; Tormo, M; Vellenga, E | 1 |
| Feldmann, L; Guerci, A; Guerci, O; Marchal, S; Merlin, JL; Missoum, N; Rose, C; Witz, F | 1 |
| Calvert, L; Claxton, D; Durett, A; Giralt, S; Hamer, J; Kantarjian, H; Khouri, I; Liang, J; Talpaz, M; Tibbits, P | 1 |
| Benvenuto, F; Carella, AM; Ferrero, R; Figari, O; Frassoni, F; Giordano, D; Podestà, M; Pollicardo, N; Pungolino, E; Raffo, MR | 1 |
| al-Sabah, A; Baines, P; Burnett, A; Hoy, T; Limaye, M; Padua, RA; Whittaker, J | 1 |
| Gieseler, F; Glasmacher, A; Kämpfe, D; Kunze, J; Nuessler, V; Valsamas, S; Wandt, H; Wilms, K | 1 |
| Capria, S; Mandelli, F; Meloni, G; Modena, V; Vignetti, M | 1 |
| Aulitzky, W; Huber, C; Peschel, C; Schneller, F; Schuler, M; Schumacher, K; Thaler, J | 1 |
| de Witte, T; Pennings, AH; Raymakers, RA; Smeets, ME; Vierwinden, G; Wessels, H | 1 |
| Diehl, V; Dimski, T; Lathan, B; Pantke, B; Schinköthe, T; Staib, P; Voliotis, D; Wiedenmann, S | 1 |
| Kasimir-Bauer, S; Scheulen, ME; Schröder, JK; Seeber, S | 1 |
| Boos, J; Creutzig, U; Feldges, A; Gadner, H; Hermann, J; Kühl, J; Niemeyer, CM; Ritter, J; Sawatzki, DB; Schwabe, D; Selle, B; Zimmermann, M | 1 |
| Baer, MR; Barone, S; Block, AW; Lawrence, D; Sait, SN; Wetzler, M | 1 |
| Fujita, H; Kimura, K; Masaoka, T; Ogawa, M; Yamada, K | 1 |
| Andreeff, M; Berman, E; Gabrilove, J; Gee, T; Gulati, S; Heller, G; Kempin, SJ; Kolitz, J; Raymond, V; Young, CW | 1 |
| Carcassonne, Y; Dufour, P; Harousseau, JL; Hayat, M; Hurteloup, P; Jaubert, J; Le Prise, PY; Monconduit, M; Reiffers, J; Rigal-Huguet, F | 1 |
8 trial(s) available for idarubicin and Blast Crisis
| Article | Year |
|---|---|
Implementing the EffTox dose-finding design in the Matchpoint trial.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Blast Crisis; Cytarabine; Humans; Idarubicin; Imidazoles; Models, Statistical; Outcome Assessment, Health Care; Pyridazines; Research Design; Vidarabine | 2017 |
[Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cyclophosphamide; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mucositis; Nausea; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Treatment Outcome; Vincristine | 2006 |
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; Child, Preschool; Creatinine; Disease-Free Survival; Female; Hemorrhage; Humans; Idarubicin; Infections; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Remission Induction; Risk Factors; Sex Factors; Survival Rate; Syndrome; Treatment Failure; Tretinoin | 2008 |
Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia--results of a phase-II trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Remission Induction; Survival Rate | 1998 |
Prognosis in adult AML is precisely predicted by the DISC-assay using the chemosensitivity-index Ci.
Topics: Adult; Aminoglutethimide; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cell Survival; Cytarabine; Danazol; Drug Screening Assays, Antitumor; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Predictive Value of Tests; Prognosis; Prospective Studies; Regression Analysis; Remission Induction; Survival Analysis; Tamoxifen; Vidarabine | 1999 |
Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Treatment Outcome | 2001 |
High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Cytogenetic Analysis; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Remission Induction; Survival Rate; Treatment Outcome | 2001 |
Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction | 1989 |
22 other study(ies) available for idarubicin and Blast Crisis
| Article | Year |
|---|---|
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Female; Forkhead Transcription Factors; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; RNA, Messenger; T-Lymphocytes, Regulatory; Transforming Growth Factor beta | 2023 |
Renal cortical necrosis secondary to thrombotic microangiopathy in the context of acute promyelocytic leukaemia blast crisis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Hemolytic-Uremic Syndrome; Humans; Idarubicin; Ischemia; Kidney; Kidney Cortex Necrosis; Leukemia, Promyelocytic, Acute; Male; Plasma; Plasmapheresis; Renal Dialysis; Respiratory Insufficiency; Tonsillitis; Tretinoin | 2013 |
The percentage of peripheral blood blasts on day 7 of induction chemotherapy predicts response to therapy and survival in patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; Cytarabine; Female; Flow Cytometry; Humans; Idarubicin; Immunophenotyping; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Young Adult | 2014 |
Enhanced invasiveness of drug-resistant acute myeloid leukemia cells through increased expression of matrix metalloproteinase-2.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Blast Crisis; Blotting, Western; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Matrix Metalloproteinase 2; Middle Aged; Neoplasm Invasiveness; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Young Adult | 2009 |
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Rate; Thiazoles; Vincristine | 2009 |
Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Disease-Free Survival; Female; Genes, Wilms Tumor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Predictive Value of Tests; Survival Rate; Time Factors; Transcription, Genetic; Treatment Outcome; WT1 Proteins; Young Adult | 2010 |
Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Remission Induction; Retrospective Studies; Survival Rate; Time Factors; Transplantation, Homologous; Vidarabine; Young Adult | 2010 |
Unique association of systemic mastocytosis and myeloid/lymphoid neoplasm in blast crisis with abnormality of FGFR1 gene.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; DNA-Binding Proteins; Fatal Outcome; Gene Rearrangement; Humans; Idarubicin; Male; Mastocytosis, Systemic; Myeloproliferative Disorders; Receptor, Fibroblast Growth Factor, Type 1; Transcription Factors | 2012 |
Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Cytarabine; Female; Flow Cytometry; Humans; Idarubicin; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Pilot Projects; Prognosis; Remission Induction | 2006 |
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Pyrimidines; Survival Rate; Treatment Outcome | 2007 |
Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bile Ducts; Blast Crisis; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Cytarabine; Drug Eruptions; Hepatocytes; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Function Tests; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2007 |
Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
Topics: Adolescent; Adult; Aging; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Etoposide; Female; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Prognosis; Risk Factors; Survival Analysis; Treatment Outcome | 2008 |
Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Blood Cell Count; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 7; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Female; Flow Cytometry; Gene Expression; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Monosomy; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Prognosis; Prospective Studies; Quinine; Remission Induction; Risk; Salvage Therapy; Treatment Outcome | 1995 |
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autolog
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; Diploidy; Etoposide; Female; Genetic Markers; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Philadelphia Chromosome; Remission Induction; Survival Rate; Vidarabine; Whole-Body Irradiation | 1995 |
Selective overshoot of Ph-negative blood hemopoietic cells after intensive idarubicin-containing regimen and their repopulating capacity after reinfusion.
Topics: Adult; Blast Crisis; Bone Marrow Transplantation; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Idarubicin; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged | 1993 |
In vitro drug resistance in acute myeloid and chronic B-lymphocytic leukaemic blasts and in normal blood and marrow populations.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Bone Marrow; Bone Marrow Cells; Cell Survival; Cells, Cultured; Cyclosporine; Daunorubicin; Drug Resistance; Drug Resistance, Multiple; Female; Fluorescent Antibody Technique; Humans; Idarubicin; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Middle Aged; Monocytes; Reference Values | 1994 |
Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
Topics: Antibiotics, Antineoplastic; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Blast Crisis; Daunorubicin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Humans; Hydrogen-Ion Concentration; Idarubicin; Isoenzymes; Leukemia, Myeloid, Acute; Poly-ADP-Ribose Binding Proteins; Prognosis; Tumor Cells, Cultured | 1996 |
Blast crisis of chronic myelogenous leukemia in long-lasting systemic lupus erythematosus: regression of both diseases after autologous bone marrow transplantation.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Blast Crisis; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Idarubicin; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lupus Erythematosus, Systemic; Methotrexate; Prednisone; Remission Induction; Transplantation, Autologous; Vincristine | 1997 |
Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by downregulating multidrug resistance.
Topics: Antibiotics, Antineoplastic; Antigens, CD34; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Bone Marrow Cells; Cell Cycle; Cell Division; Cell Survival; Cells, Cultured; Daunorubicin; Drug Resistance, Multiple; Gene Expression Regulation; Hematopoietic Stem Cells; Humans; Idarubicin; Idoxuridine; Leukemia, Myeloid, Acute; Verapamil | 1999 |
In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia.
Topics: Antineoplastic Agents; Blast Crisis; Calcium Channel Blockers; Daunorubicin; Dihydropyridines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Tumor Cells, Cultured; Verapamil | 2000 |
[A pharmacokinetic study of idarubicin hydrochloride, a new anthracycline anti-tumor drug, in patients with acute leukemia. Idarubicin Study Group].
Topics: Acute Disease; Blast Crisis; Humans; Idarubicin; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1992 |
Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Blast Crisis; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged | 1987 |